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Abstract
Neurodegenerative diseases are a growing burden in modern society, thus crucially calling for the development of
accurate diagnostic strategies. These diseases are currently incurable, a fact which has been attributed to their late
diagnosis, after brain damage has already become widespread. An earlier and improved diagnosis is necessary for
the enrolment of patients into clinical trials and can pave the way for the development of therapeutic tactics. Novel
analytical techniques, such as mass spectrometry and vibrational spectroscopy, have been able to successfully
detect and characterise neurodegenerative disorders. It is critical to globally support and make use of innovative
basic research and techniques, which could ultimately lead to the creation of a cost-effective diagnostic test.
Minimally invasive samples, such as biological fluids, have also been shown to reveal information for these diseases;
utilising them could simplify sample collection/analysis and be more preferable to patients.
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Background
In recent years, research has made great strides in deci-
phering the underlying mechanisms of neurodegenerative
diseases. It is now widely accepted that brain changes as-
sociated with the disease commence years prior to symp-
tomatology, when preventative / therapeutic strategies are
more likely to successfully intervene and decelerate, if not
cease, disease progression. The fact that neurodegenera-
tion is a slowly progressive disease can allow enough time
for a series of screening tests and potentially a timely diag-
nosis to be made. Nonetheless, currently a definitive diag-
nosis can only be provided post-mortem and a robust
means for early diagnosis remains yet to be established.
Main text
As the percentage of the population over 65 years is grow-
ing, so is the burden of neurodegenerative disorders. An es-
timated 50 million people worldwide live with dementia,
with this number getting doubled every 20 years, expected
to reach 75 million in 2030 and 131.5 million in 2050 [1].
The major and enduring healthcare costs for neurodegener-
ative disease sufferers and their families are prohibitive in
many countries and their respective health systems. For
instance, the worldwide economic burden of dementia pa-
tients alone has been estimated to rise above a US$ trillion.
It is evident that an accurate and cost-effective screening
approach could permit the development of early preventa-
tive strategies that could impact on the disease progression.
Two decades ago, the first evidence of the structure of β-
amyloid plaques was revealed by synchrotron infrared (IR)
microspectroscopy, after in situ analysis of the brain of an
Alzheimer’s disease patient [2]. Today, technological im-
provements and new techniques, such as mass spectrometry
or vibrational and nuclear magnetic resonance spectros-
copies, have emerged as promising detection tools in the
field of neurodegeneration [3–6]. Vibrational spectroscopy,
including IR and Raman, is by far the simplest method, re-
quiring less sophisticated instrumentation and consumables,
thus automatically decreasing the expenses and rendering a
potential test easily translatable (Fig. 1). So far, numerous
studies have demonstrated the efficacy of vibrational spec-
troscopy in identifying individuals with various degenerative
conditions, such as dementia or Parkinson’s disease, with
high levels of diagnostic accuracy [7, 8].
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Previous research has focused on the development of
panels of biomarkers to improve the diagnostic accuracy
for neurodegenerative diseases. However, the majority of
the employed techniques require either expensive or inva-
sive and laborious methods, including imaging and cerebro-
spinal fluid testing. In contrast, vibrational spectroscopy
has the ability to investigate and identify numerous
biological molecules simultaneously, therefore providing a
multiple marker test for an underlying pathology while
being rapid and inexpensive. Using developed machine-
learning algorithms, the system is “trained” to recognize
unique spectral markers that indicate disease; thus, when
unknown samples are introduced, it is possible to accur-
ately assess them in a traffic-light manner, with amber and
red light suggesting further investigation and disease,
respectively, while a green light would indicate absence of
disease. Accordingly, high-risk population, as well as people
with mild cognitive impairment or a traumatic brain injury
could be monitored by serial sampling, which can be easily
achieved by minimally-invasive blood tests. A detection of
brain changes early in the course of disease would allow
individuals to enroll in potential clinical trials, therefore
promoting drug development and benefiting patients. An
important advantage of this traffic-light system is that there
is no need for prior expertise in spectroscopy and spectral
analysis, with a nurse or a clinical doctor being able to
immediately interpret the result. A representative example
is the use of Raman spectroscopy during brain cancer
surgery, which can provide invaluable information to
surgeons by defining surgical margins in patients with
different grades of brain tumour severity [9].
Conclusions
Spectroscopy of biological fluids, such as blood and cere-
brospinal fluid, is anticipated to facilitate the development
of novel, cost-effective diagnostic strategies and promote
rapid primary care. Recently developed hand-held port-
able devices also facilitate point-of-care diagnostics which
could significantly expedite clinical implementation. Use
of such technologies could enhance the accuracy of
neurological diagnosis and also categorize disease types.
However, similar to any innovation pending translation in
a clinical context, spectroscopy requires a series of valid-
ation steps, including large-scale studies and coordinated
efforts across different, multidisciplinary research groups.
Both scientific and clinical communities need to embrace
non-traditional methodologies and redouble their efforts
towards the repetition and validation of the latter in order
to render them translatable in a clinical context. A vital
step for success would be to share knowledge and research
results in wide-ranging and free-access electronic plat-
forms from where patients, researchers and doctors alike
would be able to keep track with the latest advancements
in the area of neurodegeneration.
Fig. 1 The potential of biospectroscopy in a clinical diagnostic pathway. a A handheld device is used to analyse the sample (e.g., blood or CSF)
causing vibrations to its molecules. b Infrared and (c) Raman spectroscopies generate characteristic spectra which allow the identification of
biomarkers indicative of disease. d Spectral analysis then follows to classify the patients into different categories using a traffic-light system: red
suggesting disease, amber proposing high risk and further investigation and green indicate absence of disease
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